INVA

In a comparison of two large cap pharmaceutical stocks, Innoviva (INVA) emerges as the superior value option compared to Merck (MRK). INVA holds a Zacks Rank of #2 (Buy) versus MRK's #3 (Hold), and demonstrates significantly better valuation metrics including a forward P/E of 9.12 versus MRK's 53.42, a PEG ratio of 3.04 versus 6.42, and a P/B ratio of 1.24 versus 8.4. INVA received a Value grade of A while MRK received a C.

Zacks highlights Innoviva (INVA) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/E ratio of 10.12 compared to its industry average of 17.64, and shows favorable valuations across multiple metrics including P/S ratio of 3.46 and P/CF ratio of 20.06, suggesting it is currently undervalued.